CA Patent

CA2581426A1 — Sulfonamide compounds

Assigned to Janssen Pharmaceutica NV · Expires 2006-04-06 · 20y expired

What this patent protects

Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

USPTO Abstract

Certain sulfonamide compounds are dual CCK1/CCK2 inhibitors useful in the treatment of CCK1/CCK2 mediated diseases.

Drugs covered by this patent

dabrafenib-mesylate (DABRAFENIB MESYLATE)

Patent Metadata

Patent number: CA2581426A1
Jurisdiction: CA
Classification: —
Expires: 2006-04-06
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.